Brian L. Hood

ShapeUpLMD automates ROI optimization for laser microdissection, improving tumor purity and spatial accuracy in multi-omic tissue profiling.

This study uses proteogenomics to identify ancestry-specific and shared molecular drivers in prostate cancer, revealing distinct biological programs and improving risk prediction.

The paper identifies conserved protein alterations and elevated MUC16 in low-grade serous ovarian cancers through quantitative proteomics and validation across multiple datasets.

ProteoMixture estimates cell type proportions in bulk tissue proteomics data using optimized protein signatures validated on high-grade serous ovarian cancer samples.

This paper standardizes a proteotype analysis workflow across multiple international sites to enable distributed, reproducible proteomic data generation for precision medicine.

This study shows that Cdk2 is required for platelet activation by inhibiting PP1 phosphatase activity and promoting Erk activation through phosphorylation of PPP1R12a.

This study identifies HN1 as a predictive and pharmacodynamic biomarker of metformin response in endometrioid endometrial cancer, showing it is elevated in responders and decreases after treatment.